William Blair Brokers Reduce Earnings Estimates for Repligen

Repligen Co. (NASDAQ:RGEN) – Analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Repligen in a research note issued to investors on Friday, February 21st. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.33 per share for the quarter, down from their prior estimate of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q2 2025 earnings at $0.45 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.48 EPS, FY2025 earnings at $1.71 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.64 EPS and FY2026 earnings at $2.28 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.

Several other equities research analysts have also recently weighed in on RGEN. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Friday. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday. Finally, JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Down 2.3 %

Shares of RGEN stock opened at $158.99 on Monday. The stock has a market capitalization of $8.91 billion, a PE ratio of -311.75, a P/E/G ratio of 4.54 and a beta of 0.99. Repligen has a 1-year low of $113.50 and a 1-year high of $203.13. The business has a 50-day moving average of $155.22 and a 200 day moving average of $148.59. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RGEN. CWM LLC raised its position in shares of Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 114 shares in the last quarter. Creative Planning grew its stake in shares of Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock worth $762,000 after buying an additional 1,259 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Raymond James & Associates grew its stake in shares of Repligen by 49.3% in the 3rd quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock worth $12,244,000 after buying an additional 27,158 shares during the last quarter. Finally, Greenleaf Trust purchased a new stake in shares of Repligen in the 3rd quarter worth approximately $226,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.